Pharmacy benefit managers, pharmacies, and pharmacogenomic testing: Prescription for progress?

Science Translational Medicine

Volumn 2, Issue 44, 2010, Pages

  Topol, Eric J ^a  

^a SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL;

CONSUMER ADVOCACY; CORONARY STENT; DISEASE PREDISPOSITION; DRUG COST; DRUG INDUSTRY; DRUG INFORMATION; DRUG SAFETY; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; NOTE; PHARMACEUTICAL CARE; PHARMACOGENOMICS; PHARMACY BENEFIT MANAGER; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; ARTICLE; CLINICAL PRACTICE; ECONOMICS; MANAGEMENT; PERSONALIZED MEDICINE; PHARMACIST; PHARMACOGENETICS; PHARMACY;

HUMANS; INDIVIDUALIZED MEDICINE; PHARMACIES; PHARMACISTS; PHARMACOGENETICS; PHARMACY ADMINISTRATION; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS;

EID: 77955591464     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001067     Document Type: Note

References (17)

1. C. Y. Johnson, "Personalized prescription: CVS, Medco at vanguard of effort to match patients, drugs by genetic tests," Boston Globe, 25 January 2010 (http://www.boston.com/business/healthcare/articles/2010/01/25/ personalized-prescription/).
2. E. Singer, "Genetic testing heads to the pharmacy," Technology Review, 10 February 2010 (http://www.technologyreview.com/biomedicine/24513/).
3. J. Carey, "Personalized medicine spurred by Medco's cost-saving gene tests," Bloomberg, 11 march 2010 (http://www.businessweek.com/news/2010- 03-11/personalized-medicine-spurred-by-medco-s-cost-saving-gene-tests.html).
4. R. S. Epstein, T. P. Moyer, R. E. Aubert, D. J. O'Kane, F. Xia, R. R. Verbrugge, B. F. Gage, J. R. Teagarden, Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55, 2804-2812 (2010).
5. A. W. Matthews, "Medco makes push into genetic tests," Wall Street Journal, 19 May 2010 (http://online.wsj.com/article/NA-WSJ-PUB:BT-CO- 20100518-714649.html).
6. E. J. Topol, The consumer movement in health care. Pharos Alpha Omega Alpha Honor Med. Soc. 73, 34-35 (2010).
7. G. Gatyas, "IMS health reports U.S. prescription sales grew 5.1 percent in 2009, to $300.3 billion," IMS, 1 April 2010.
8. S. B. Damani, E. J. Topol, the case for routine genotyping in dual-antiplatelet therapy. J. Am. Coll. Cardiol. 56, 109-111 (2010).
9. A. Pollack, "Start-up may sell genetic tests in stores," New York Times, 10 May 2010 (http://www.nytimes.com/2010/05/11/health/11gene.html).
10. A. Pollack, "Walgreens delays selling personal genetic test kit," New York Times, 12 May 2010.
11. J. C. Dooren, "House panel probes gene tests," Wall Street Journal, 20 May 2010 (http://online.wsj.com/article/ SB10001424052748704691304575254844175966082.html?KEYWORDS= House+panel+probes+gene+tests).
12. "Direct-to-Consumer Genetic Tests," Government Accountability Office Testimony Before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, U.S. House of Representatives, 22 July 2010 (http://www.gao.gov/new.items/d10847t.pdf).
13. S. Murphy, "Thomas Goetz has the wrong debate. FDA doesn't intend to restrict," The Gene Sherpa, http://thegenesherpa.blogspot.com/2010/05/ thomas-goetz-has-wrong-debate-fda.html (22 May 2010).
14. T. Munnecke, Health Blog comment on "Pathway, 23andMe, Navigenics gene tests to face House scrutiny," Wall Street Journal, 20 May 2010 (http://blogs.wsj.com/health/2010/05/20/pathway-23andme-navigenics-gene-tests- to-face-house-scrutiny/tab/comments/).
15. E. A. Ashley, A. J. Butte, M. T. Wheeler, R. Chen, T. E. Klein, F. E. Dewey, J. T. Dudley, K. E. Ormond, A. Pavlovic, A. A. Morgan, D. Pushkarev, N. F. Neff, L. Hudgins, L. Gong, L. M. Hodges, D. S. Berlin, C. F. Thorn, K. Sangkuhl, J. M. Hebert, M. Woon, H. Sagreiya, R. Whaley, J. W. Knowles, M. F. Chou, J. V. Thakuria, A. M. Rosenbaum, A. W. Zaranek, G. M. Church, H. T. Greely, S. R. Quake, R. B. Altman, Clinical assessment incorporating a personal genome. Lancet 375, 1525-1535 (2010).
16. D. Ge, J. Fellay, A. J. Thompson, J. S. Simon, K. V. Shianna, T. J. Urban, E. L. Heinzen, P. Qiu, A. H. Bertelsen, A. J. Muir, M. Sulkowski, J. G. McHutchison, D. B. Goldstein, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
17. Funding: NIH/National Center for Research Resources grant UL1 RR025774. Competing interests: E.J.T. is an advisor to Sanofi-Aventis and Daiichi Sankyo, which manufacture clopidogrel and prasugrel, respectively, and to Quest Diagnostics. E.J.T. has no relationship with any consumer genomic testing company or any PBM or drugstore chain.